This study aimed to evaluate the effectiveness of
tamsulosin monotherapy for the treatment of ureteral
stent-related symptoms (SRSs) and compare it with that of
solifenacin monotherapy and combined
therapy of
tamsulosin and silifenacin. Randomized controlled trials (RCTs), which evaluated the effectiveness of
tamsulosin for the treatment of SRSs, were searched from the databases PubMed, EMBASE and the Cochrane Library published up to November 2018. Eight RCTs involving 1087 participants were finally included in this meta-analysis. The results showed that
tamsulosin monotherapy could significantly decrease the urinary symptoms [mean difference (MD) -7.56, 95% confidence interval (CI) (-11.47, -3.65), P=0.0001] and body
pain [MD -5.25, 95% CI (-8.03, -2.46), P=0.0002], and improve the sexual performance [MD -1.06, 95% CI (-1.89, -0.24), P=0.01] compared with the control group. Moreover, there was no significant difference between
tamsulosin monotherapy and
solifenacin monotherapy in all outcomes except for significantly better sexual performance in
solifenacin group [MD 0.29, 95% CI (0.06, 0.51), P=0.01]. In addition, the effectiveness of combined
therapy of
tamsulosin and
solifenacin was not superior to that of
tamsulosin monotherapy. Our study demonstrated that
tamsulosin monotherapy was effective for the treatment of patients with SRSs; evident superiority could not be found for
therapy of
tamsulosin and
solifenacin combined.